EU/3/03/154

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in July 2017 at the end of the 10-year period of market exclusivity.

On 9 July 2003, orphan designation (EU/3/03/154) was granted by the European Commission to OTL Pharma, France, for hydroxyurea for the treatment of sickle cell syndrome. The sponsorship was transferred to Addmedica SAS, France, in October 2006.

Hydroxyurea has been authorised in the EU as Siklos since 29 June 2007.

Key facts

Active substance
Hydroxyurea
Medicine name
Siklos
Disease / condition
Treatment of sickle cell syndrome
Date of decision
09/07/2003
Outcome
Expired
Orphan decision number
EU/3/03/154

Sponsor's contact details

Addmedica SAS
101 rue Saint Lazare
75009 Paris
France
Telephone: + 33 1 72 69 01 86
Telefax: + 33 1 73 72 94 13
E-mail: contact@addmedica.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating